FEVERY PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
FEVERY PHARMA
Largest movements
- Receivables within one year -€48,860
down €48,860 (-71.4%), from €68,411 to €19,551
of which Trade receivables: -€50,000
- Cash +€47,399
up €47,399 (+26.6%), from €178,396 to €225,795
mainly Other debts (+€196,122) and Net result for the year (+€160,584)
- Debts after one year -€239,598
down €239,598 (-82.7%), from €289,598 to €50,000
of which Other amounts payable: -€214,598
- Other debts +€196,122
up €196,122 (+490.9%), from €39,948 to €236,070
- Reserves +€33,918
up €33,918 (+3.7%), from €917,791 to €951,709
- Tax, wage and social debts +€25,307
up €25,307 (+329.6%), from €7,677 to €32,984
of which Taxes: +€22,407
- Accrued charges and deferred income -€19,876
down €19,876 (-93.8%), from €21,183 to €1,307
- Financial income +€49,226
up €49,226 (+3947.7%), from €1,247 to €50,473
- Financial charges -€20,249
down €20,249 (-90.5%), from €22,387 to €2,138
- Taxes +€15,096
up €15,096 (+39.7%), from €38,006 to €53,102
- Gross operating margin +€8,674
up €8,674 (+5.5%), from €157,802 to €166,477
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,504,740 | €1,503,202 | -€1,538 | -0.1% |
| Fixed assets | 21/28 | €1,257,761 | €1,257,761 | = | 0.0% |
| Financial fixed assets | 28 | €1,257,761 | €1,257,761 | = | 0.0% |
| Current assets | 29/58 | €246,978 | €245,440 | -€1,538 | -0.6% |
| Amounts receivable within one year | 40/41 | €68,411 | €19,551 | -€48,860 | -71.4% |
| Trade receivables | 40 | €68,150 | €18,150 | -€50,000 | -73.4% |
| Other amounts receivable | 41 | €261 | €1,401 | +€1,140 | +436.5% |
| Cash at bank and in hand | 54/58 | €178,396 | €225,795 | +€47,399 | +26.6% |
| Deferred charges and accrued income | 490/1 | €171 | €94 | -€77 | -45.0% |
| Total equity and liabilities | 10/49 | €1,504,740 | €1,503,202 | -€1,538 | -0.1% |
| Equity | 10/15 | €1,145,097 | €1,179,015 | +€33,918 | +3.0% |
| Contributions | 10/11 | €227,306 | €227,306 | = | 0.0% |
| Reserves | 13 | €917,791 | €951,709 | +€33,918 | +3.7% |
| Distributable reserves | 133 | €917,791 | €951,709 | +€33,918 | +3.7% |
| Amounts payable | 17/49 | €359,642 | €324,187 | -€35,456 | -9.9% |
| Amounts payable after more than one year | 17 | €289,598 | €50,000 | -€239,598 | -82.7% |
| Financial debts | 170/4 | €75,000 | €50,000 | -€25,000 | -33.3% |
| Other amounts payable | 178/9 | €214,598 | - | -€214,598 | |
| Amounts payable within one year | 42/48 | €48,862 | €272,880 | +€224,018 | +458.5% |
| Trade debts | 44 | €1,237 | €3,826 | +€2,589 | +209.2% |
| Suppliers | 440/4 | €1,237 | €3,826 | +€2,589 | +209.2% |
| Taxes, remuneration and social security | 45 | €7,677 | €32,984 | +€25,307 | +329.6% |
| Taxes | 450/3 | €4,777 | €27,184 | +€22,407 | +469.1% |
| Remuneration and social security | 454/9 | €2,900 | €5,800 | +€2,900 | +100.0% |
| Other amounts payable | 47/48 | €39,948 | €236,070 | +€196,122 | +490.9% |
| Accrued charges and deferred income | 492/3 | €21,183 | €1,307 | -€19,876 | -93.8% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €1,305 | - | -€1,305 | |
| Other operating charges | 640/8 | €1,094 | €1,126 | +€33 | +3.0% |
| Gross operating margin | 9900 | €157,802 | €166,477 | +€8,674 | +5.5% |
| Operating profit (loss) | 9901 | €155,404 | €165,350 | +€9,947 | +6.4% |
| Financial income | 75/76B | €1,247 | €50,473 | +€49,226 | +3947.7% |
| Recurring financial income | 75 | €1,247 | €50,473 | +€49,226 | +3947.7% |
| Financial charges | 65/66B | €22,387 | €2,138 | -€20,249 | -90.5% |
| Recurring financial charges | 65 | €22,387 | €2,138 | -€20,249 | -90.5% |
| Profit (loss) for the period before taxes | 9903 | €134,264 | €213,686 | +€79,422 | +59.2% |
| Income taxes | 67/77 | €38,006 | €53,102 | +€15,096 | +39.7% |
| Profit (loss) for the period | 9904 | €96,258 | €160,584 | +€64,326 | +66.8% |
| Profit (loss) for the period to be appropriated | 9905 | €96,258 | €160,584 | +€64,326 | +66.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.